Maggie Cheang | Team Leader, Genomic Analysis – Clinical Trials
Institute of Cancer Research

Maggie Cheang, Team Leader, Genomic Analysis – Clinical Trials, Institute of Cancer Research

Dr. Maggie Cheang is a Team Leader of the Genomic Analysis – Clinical Trials in Division of Clinical Studies and the Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU). Her research focus is to develop genomics classifiers for tumour subtypes and to determine their clinical utility to predict sensitivity to therapeutic agents in phase II and III clinical trials.

Dr. Cheang grew up in Vancouver, Canada and obtained her PhD in Pathology and Laboratory Medicine from the University of British Columbia in Canada. She then received a prestigious Canadian Cancer Society/Terry Fox Foundation Postdoctoral Fellowship to train with Professor Charles Perou, a pioneer in identifying subtypes of breast cancer, at the Lineberger Comprehensive Cancer Center at the University of North Carolina, US.

Her research achievements have been internationally recognised by numerous awards, grants and memberships. She was a Merit Award recipient at the American Society of Clinical Oncology Meeting in 2011 and received a Clinical Science Scholar Scholarship at the CTRC-AACR San Antonio Breast Cancer Symposium in 2011, and two Novartis Oncology Young Canadian Investigator Awards (2011, 2008)

She consults on several trial management and translational research committees for phase II and III trials. As a mark of her standing in the field, she currently serves as a member of the Scientific Grant Committee for Breast Cancer Now, an Associate Editor of BMC Cancer and npj Breast Cancer respectively, Chair for the National Cancer Research Institute (NCRI) CM-Path Clinical Trials Pathology Advisory Group (CT-PAG) and member within the Cellular Molecular – Pathology Initiative (Discovery work stream).

Her work has been instrumental in the identification and validation of multiple clinically recognised biomarkers, one of which has been implemented into clinical practice guidelines. Dr Cheang co-invented the 50 genes-based classifiers for the breast cancer intrinsic subtypes. This assay, commonly known as PAM50, is currently licensed by NanoString® Technologies as Prosigna and is integrated into multiple international clinical practice guidelines including the German Association of Gynecological Oncology (AGO), St. Gallen International Breast Cancer, European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines for clinical subtype classification in breast cancer.


Festival of Biologics Day 3 @ 12:30

Pros and cons of several trial designs for immunotherapy and the choice of endpoints

  • Clinical development of immune-oncology (IO) agents presents both opportunities and challenges and not all patients benefit to the same extent
  • Many factors influence trial designs and could potentially threat success of promising IO drugs:
  • Response evaluation criteria
  • Surrogate endpoints for efficacy still be in used and the need for validated  specifically for IO trials.
  • Biomarker-driven clinical studies in order to select appropriated patients.
  • Long-term toxicity monitoring and Optimizing the design of new IO agents
  • last published: 17/Sep/21 16:05 GMT
    last published: 17/Sep/21 16:05 GMT
    last published: 17/Sep/21 16:05 GMT
    last published: 17/Sep/21 16:05 GMT

    back to speakers